| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Lease right-of-use | 0 | |||
| Investment in oravax medical | 1,500,000 | |||
| Goodwill | 10,498,539 | |||
| Total non-current assets | 11,998,539 | |||
| Prepaid expenses | 1,339,503 | |||
| Marketable securities | 3,605,508 | |||
| Cash | 207,553 | |||
| Total current assets | 5,152,564 | |||
| Total assets | 17,151,103 | |||
| Due to mymd fl shareholders-Related Party | 29,982 | |||
| Lease liability | 0 | |||
| Dividends payable | 2,843,017 | |||
| Derivative liability | 0 | |||
| Trade and other payables | 2,677,150 | |||
| Total current liabilities | 5,550,149 | |||
| Total liabilities | 5,550,149 | |||
| Convertible preferred stock, value-Series GConvertible Preferred Stock | 8,737,000 | |||
| Convertible preferred stock, value-Series FOne Convertible Preferred Stock | 2,065,426 | |||
| Convertible preferred stock, value-Series FConvertible Preferred Stock | 5,130,667 | |||
| Convertible preferred stock discount-Series GConvertible Preferred Stock | 7,544,000 | |||
| Convertible preferred stock discount-Series FOne Convertible Preferred Stock | 2,065,426 | |||
| Convertible preferred stock discount-Series FConvertible Preferred Stock | 0 | |||
| Convertible preferred stock derivative-Series FConvertible Preferred Stock | 0 | |||
| Total mezzanine equity | 6,323,667 | |||
| Accumulated deficit | -133,849,089 | |||
| Preferred stock, value-Series DConvertible Preferred Stock | 144,524 | |||
| Common stock, par value 0.001, 1,250,000,000 shares authorized, 29,383,743 and 3,363,603 shares issued and outstanding as of june 30, 2025 and december 31, 2024, respectively | 29,384 | |||
| Additional paid in capital | 138,952,468 | |||
| Total stockholders equity | 5,277,287 | |||
| Total liabilities and stockholders equity | 17,151,103 | |||
TNF Pharmaceuticals, Inc. (TNFA)
TNF Pharmaceuticals, Inc. (TNFA)